Friday, April 11, 2008
Comment Rejection
Oops. I accidentally rejected a comment from Jeffrey Dach. I meant to accept it, but clicked the wrong link. Please re-post.
Subscribe to:
Post Comments (Atom)
skip to main |
skip to sidebar
Email
Psychiatric medications, science, marketing, psychiatry in general, and occasionally clinical psychology. Questioning the role of key opinion leaders and the use of "science" to promote commercial ends rather than the needs of people with mental health concerns.
Blog Archive
-
▼
2008
(103)
-
▼
April
(14)
- Paxil, Lies, and the Lying Researchers Who Tell Them
- Military Analysts and Key Opinion Leaders
- Don't Believe the CPA's Hype About Not Believing t...
- Key Opinion Leaders, Osteoporosis, Vioxx, Psychiat...
- Academics, Atypicals, and Marketing
- Antidepressant PR Gone Wild
- Comment Rejection
- Key Opinion Leader Is Unfairly Disparaged
- Bipolar Child Key Opinion Leader: I Get Money
- The Lingering Stain of Paxil Study 329
- Vioxx Goes The Way Of Zyprexa
- What Tangled Webs We Weave...
- Does GSK Love Bad Publicity?
- Abilify for Depression: Second Round a Lot Like th...
-
▼
April
(14)
Academia
Pharma: General
Psychiatry and Psychology
Scientific Misconduct
About Me
- CL Psych
- I'm an academic with a respectable amount of clinical experience and no drug industry funding. Given my lack of time, don't expect multiple daily updates. Certain things about clinical psychology, the drug industry, psychiatry, and academics drive me nuts, and you'll probably pick up on these pet peeves before long...
Translate this page
Subscribe Via Email
1 comment:
According to Dr. Irving Kirsch in Prevention & Treatment, “there is now unanimous agreement that the mean difference between response to SSRI antidepressant drugs and response to inert placebo is very small. It is so small that, despite sample sizes involving hundreds of participants, 57% of the SSRI trials funded by the pharmaceutical industry failed to show a significant difference between drug and placebo. Most of these negative data were not published and were accessible only by gaining access to US Food and Drug Administration (FDA) documents.
Various methods were used to manipulate the results of SSRI drug studies to insure a favorable outcome:
1) Responders to the placebo are eliminated at the beginning of the study. (Placebo washout)
2) Benzodiazepine sedatives were given to mask the SSRI induced agitation.
3) Unfavorable drug studies are buried in the file cabinet and not disclosed to the public.
4) Miscoding suicidal events as "emotional lability", and homicidal events as "aggression" to hide suicidal events from regulators.
5) False attribution of suicide to the placebo arm.
6) Hiring ghost writers to make the medical articles more favorable.
7) Cash settlements for SSRI drug litigants which seals records and withholds unfavorable drug studies from the public.
For more information and links see my Paxil, Prozac, and SSRI Induced Suicide Newsletter
Jeffrey Dach MD
Post a Comment